Meta ‐Analysis of Clinical Outcomes of PCSK9 Modulators in Patients with Established ASCVD

ConclusionThese findings suggest a class effect for favorable lipid changes and a low risk of serious adverse events among pharmacologic agents targeting PCSK9. Although there is compelling evidence that PCSK9-targeting agents reduce the risk of some cardiovascular outcomes, adequately powered studies with longer follow-up may be needed to fully characterize the magnitude of benefits across the cardiovascular spectrum.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - October 17, 2021 Category: Drugs & Pharmacology Authors: Azita H. Talasaz, Ai ‐Chen (Jane) Ho, Fawzia Bhatty, Rachel A. Koenig, Dave L. Dixon, William L. Baker, Benjamin W. Van Tassell Tags: TI ON ADVANCES IN CARDIOVASCULAR PHARMACOTHERAPY Source Type: research